Markets:

Overview

News

Currencies

International

Treasuries

Bavarian Nordic R/I ADR (OP:BVNRY)

9.320 +0.084 (+0.91%)

Streaming Delayed Price Updated: 3:54 PM EDT, Jun 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Bavarian Nordic R/I ADR

< Previous 1 2 3 Next >

UK Secures Additional Doses Of Bavarian Nordic Mpox Vaccine To Combat New Variant Threat ↗

September 17, 2024

The UK government has purchased 150,000 mpox vaccine doses from Bavarian Nordic, enhancing its response to clade I mpox, while partnering with WHO and UNICEF.

Via Benzinga

Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows ↗

September 06, 2024

Moderna is conducting a Phase 1/2 trial of mRNA-1769, a potential mpox vaccine for adults. Early research shows it may outperform Bavarian Nordic's Jynneos in reducing severe disease in monkeys.

Via Benzinga

Mpox Vaccines: Challenges Persist as Congo Receives First Batch Of Doses Almost 2 Years After It Declared Epidemic ↗

September 06, 2024

The European Commission's first delivery of mpox vaccines to Congo aims to combat the outbreak, despite challenges in distribution and approval.

Via Benzinga

WHO Seeks $135M In Funding To Fight Mpox: Outbreak 'Can Be Controlled, And Can Be Stopped' ↗

August 26, 2024

To fight the mpox outbreak in Africa, the World Health Organization calls for funding help for its six-month plan.

Via Benzinga

Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain ↗

August 26, 2024

Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing...

Via Benzinga

Bavarian Nordic Recruits US Firm For Packaging Services For Its Monkeypox Vaccine ↗

August 19, 2022

Via Benzinga

3 Promising Vaccine Stocks To Watch In The Event Of A Mpox Surge ↗

August 19, 2024

Mpox rerun is making these stocks soar. But a non-vaccine approach could yield greater gains.

Via Talk Markets

Mpox Variant Sparks Global Concern As Europe, China Ramp Up Screening ↗

August 19, 2024

Increased screening for deadly new version of mpox is seen in Europe and China. More imported cases are expected. New vaccines are being developed.

Via Benzinga

Mpox Vaccine Maker Bavarian Nordic Targets Broader Access With European Submission For Imvanex Adolescent Use During WHO Emergency ↗

August 16, 2024

Bavarian Nordic submits data to European Medicines Agency seeking approval to extend Imvanex vaccine use to adolescents. New trials in younger children planned as global demand for smallpox and mpox...

Via Benzinga

Emergent Biosolutions, Bavarian Nordic, GeoVax And SIGA Technologies Shares Are Making Big Moves Thursday: What's Going On? ↗

August 15, 2024

Several healthcare stocks associated with mpox are seeing increased attention Thursday after the World Health Organization declared a public health emergency in response to an mpox outbreak in Africa.

Via Benzinga

WHO Declares Mpox Public Health Emergency: 'Coordinated International Response Essential' To Halt Outbreak ↗

August 14, 2024

A public health emergency for mpox in Africa saw vaccine stocks jump Wednesday. A look at the stocks and what's next for fighting the virus.

Via Benzinga

Bavarian Nordic Beefs Up Chikungunya Vaccine Race With Valneva With Encouraging Late-Stage Trial Data ↗

June 20, 2023

Bavarian Nordic A/S's (OTC: BVNRY) phase 3 chikungunya virus vaccine (CHIKV VLP (PXVX0317) clinical trial has hit its primary endpoint in

Via Benzinga

Monkeypox Vaccine Maker Bavarian Nordic Bets $380M On Emergent Bio's Travel Vaccines ↗

February 15, 2023

Via Benzinga

West Africa-Based Studies Show JNJ, Merck's Ebola Vaccines Provide Lasting Antibodies ↗

December 15, 2022

Via Benzinga

Threats For New Outbreak Looms, As Scientists Signal Deadly Monkeypox Variant Circulating In Central Africa ↗

November 03, 2022

Researchers have warned that a dangerous monkeypox variant with a fatality rate as high as 10% is circulating in Central Africa, which could trigger new global outbreaks. After analyzing 1,463 cases...

Via Benzinga

White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox ↗

September 02, 2022

Via Benzinga

Is Monkeypox Outbreak Cooling? Health Officials Says Virus Transmission Has Slowed ↗

August 26, 2022

Via Benzinga

SIGA Tech Made The Smallpox Treatment As Post-9/11 Bioterrorism Defense: Report ↗

August 25, 2022

In an effort to prevent bioterrorism attacks, just in case, SIGA Technologies Inc (NASDAQ: SIGA) started working on the smallpox treatment, Tpoxx, after the 9/11 terrorist attack that shook the world....

Via Benzinga

3 Top Monkeypox Stocks to Buy Right Now ↗

August 24, 2022

With cases of a frightening disease spreading to all 50 states, it’s now time to consider the top monkeypox stocks to buy right now.

Via InvestorPlace

PTON Stock Pops as Peloton Products Launch on Amazon ↗

August 24, 2022

Peloton (PTON) stock is getting a boost on Wednesday after the fitness company's products started selling on Amazon (AMZN).

Via InvestorPlace

BVNRY Stock Alert: What to Know as Bavarian Nordic Signs Supply Agreement ↗

August 24, 2022

Bavarian Nordic (BVNRY) stock is on the move Wednesday after the monkeypox vaccine company signed a supply agreement with PAHO.

Via InvestorPlace

Benzinga Before The Bell: Top Amazon Seller Succumbs To Economic Meltdown, Twitter To Tackle Toxic Content, Spam Bots, Bed Bath & Beyond Secures Loan Deal As It Tries To Stay Afloat And Other Top Financial Stories Wednesday, August 24 ↗

August 24, 2022

CNBC Top Amazon Seller Succumbs To Economic Meltdown

Via Benzinga

Bavarian Nordic Making All Efforts To Stretch Capacity To Boost Monkeypox Vaccine Supplies ↗

August 24, 2022

Bavarian Nordic A/S (OTC: BVNRY) said it was making "every effort" to meet the high demand for its monkeypox vaccine worldwide as it kept its business outlook for the year.

Via Benzinga

Experts Cast Doubt On Dependence On Monkeypox Vaccine Amid Limited Trial Data, Supply Crunch ↗

August 23, 2022

The only FDA-approved monkeypox vaccine from Bavarian Nordic A/S (OTC: BVNY) is in short supply.

Via Benzinga

Applied DNA Seeks Approval For PCR-Based Monkeypox Virus Test ↗

August 19, 2022

Via Benzinga

Biden Officials Seek To Boost Supply For Monkeypox Vaccines, Treatment ↗

August 18, 2022

Top Biden administration officials are poised to lay out new steps to accelerate the U.S. response amid the spread of monkeypox and demand for vaccines & treatments.

Via Benzinga

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher ↗

August 17, 2022

These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up.

Via InvestorPlace

The Only Monkeypox Vaccine Maker Finds It Difficult To Meet Accelerating Demand ↗

August 17, 2022

Bavarian Nordic A/S (OTC: BVNKF), the only company with an approved vaccine for monkeypox, said it’s no longer sure it can meet demand as cases continue to rise worldwide,

Via Benzinga

Plan To Extend Supply Of Monkeypox Vaccine On Cusp Of Emergency Clearance: Report ↗

August 09, 2022

A plan to extend the limited supply of monkeypox vaccine in order to provide additional doses may soon be receiving emergency clearance by U.S. health officials.

Via Benzinga

3 Monkeypox Stocks to Buy as Biden Declares Public Health Emergency ↗

August 05, 2022

Monkeypox stocks are about to rise now that the White House has declared the virus a public health emergency. Here are the stocks to watch.

Via InvestorPlace

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Bavarian Nordic R/I ADR (OP:BVNRY)

Headline News about Bavarian Nordic R/I ADR

Starting at $3.75/week.

Subscribe Today